2Venning VA, Taghipour K, Mohd Mustapa MFet al. British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012. Br J Dermatol2012; 167: 1200–14.
3Kasperkiewicz M, Eming R, Behzad Met al. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges2012; 10: 727–31.
4Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol2013; 68: 499–506.
6Smolen JS, Keystone EC, Emery Pet al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis2007; 66: 143–50.
8Gregoriou S, Giatrakou S, Theordoropoulos Ket al. Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial. Dermatology2014; 228: 158–65.
10Hoyer BF, Mumtaz IM, Yoshida Tet al. How to cope with pathogenic long-lived plasma cells in autoimmune diseases. Ann Rheum Dis2008; 67 (Suppl. 3): iii87–9.
Please check your email for instructions on resetting your password.
If you do not receive an email within 10 minutes, your email address may not be registered,
and you may need to create a new Wiley Online Library account.
Request Username
Can't sign in? Forgot your username?
Enter your email address below and we will send you your username
If the address matches an existing account you will receive an email with instructions to retrieve your username
The full text of this article hosted at iucr.org is unavailable due to technical difficulties.
